Analysts have revised their price target for Prestige Consumer Healthcare downward to $78.00 from $80.17. This reflects adjusted expectations based on updated growth and valuation metrics.
What's in the News
- Between July 1, 2025 and September 30, 2025, Prestige Consumer Healthcare repurchased 1,150,129 shares, representing 2.34% of shares, for $75 million. The total buyback since May 14, 2024 now stands at 2,298,247 shares, or 4.65%, for $161.18 million. (Key Developments)
- The company reaffirmed its earnings guidance for Fiscal 2026, projecting revenue in the range of $1,100 to $1,115 million and an organic revenue decline of approximately 1.5% to 3.0%. (Key Developments)
- Prestige Consumer Healthcare signaled its intention to pursue acquisitions and investments, with leadership highlighting over $1 billion in expected cash flow over the next four years to support M&A activities. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased from $80.17 to $78.00, reflecting a modest downward adjustment.
- The discount rate has risen slightly from 6.78% to 6.96%.
- The revenue growth projection has increased from 0.96% to 1.47%.
- Net profit margin has edged up from 20.49% to 20.57%.
- The future P/E ratio has fallen from 19.83x to 17.19x.
Have other thoughts on Prestige Consumer Healthcare?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.